CTRI/2018/11/016271已完成1 期
A Randomized, Double-Blind, Placebo-Controlled, three arms Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence and Safety of PimecrolimusCream, 1% (Encube Ethicals Private Limited)withElidel® (Pimecrolimus) Cream, 1% (Valeant PharmaceuticalsNorth America LLC) in the Treatment of Mild to Moderate Atopic Dermatitis
Encube Ethicals Private Ltd0 个研究点目标入组 588 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 588
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Non-immunocompromised male or non-pregnant, non-lactating female aged 12 years and older with a clinical diagnosis of mild to moderate atopic at the time of signing the informed consent.
- •2.Subjects have confirmed diagnosis of atopic dermatitis for at least 3 months.
- •3.Subject with clinical diagnosis of mild to moderate atopic dermatitis that has failed to respond adequately to other topical prescription treatments for atopic dermatitis, or for whom those treatments are not advisable per Investigator.
- •4.Subjects having an Investigatorâ??s Global Assessment(IGA) of disease severity of mild or moderate at baseline. [a score of 2 (mild) or 3 (moderate)]and SCORAD score of disease severity should be in > 15 and <50.
- •5.Subjects having an affected area of AD involvement of at least 5% Body Surface Area (BSA) at baseline, as defined by the Hanifin and Rajkacriteria.
- •6.Subject is capable of understanding the purposes and risks of the trial and has given written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- •7.Subject treated with a bland emollient for at least 7 days prior to baseline.
- •8.Both male and female subjects of child bearing potential must be practicing adequate contraception (for example total abstinence, intrauterine device, a double-barrier method, oral, transdermal, injected, or implanted non-hormonal or hormonal contraceptive) throughout the study and female subjects of childbearing potential must not be/likely to be pregnant or lactating and must have a negative serum pregnancy test at screening and negative urine pregnancy test at randomization.
- •9.Subject agrees to compliance with the protocol and adheres to the protocol requirements for the entire study period.
排除标准
- •1.Subjects with diagnosis of atopic dermatitis for less than 3 months.
- •2.Reports active cutaneous bacterial or viral infection in any treatment area at baseline (e.g. Clinically infected atopic dermatitis).
- •3.Sunburn, extensive scarring, or pigmented lesion(s) in any treatment area at baseline, which would interfere with evaluations.
- •4.History of confounding skin conditions, e.g., psoriasis, rosacea, erythroderma, orichthyosis.
- •5.Females who are pregnant, lactating or likely to become pregnant during the study.
- •6.History or presence of Nethertonâ??s Syndrome, immunological deficiencies or diseases, HIV, diabetes, malignancy, serious active or recurrent infection, clinically significant severe renal insufficiency or severe hepatic disorders.
- •7.Use within one month prior to baseline of 1) oral or intravenous corticosteroids, 2) UVA/UVB therapy, 3) PUVA (psoralen plus ultraviolet A) therapy, 4) tanning booths, 5) nonprescription UV light sources, 6) immunomodulators or immunosuppressive therapies, 7) interferon, 8) cytotoxic drugs, 9) Tacrolimus, or 10) Pimecrolimus.
- •8.Use within 14 days of baseline of: 1) systemic antibiotics, 2) calcipotriene or other Vitamin D preparations, or 3) retinoids.
- •9.Use within 7 days prior to baseline of: 1) antihistamines, 2) topical antibiotics, 3) topical corticosteroids or 4) other topical drug products.
- •10.Use within 24 hours prior to baseline of any topical product (e.g., sunscreens, lotions, creams) in the areas to be treated, except for bland emollient (moisturizer).
- •11. Known allergy or hypersensitivity to Pimecrolimusor any other component of the test product or RLD.
- •12.Not willing to minimize or avoid natural and artificial sunlight exposure during treatment.
- •13.Subjects with clinically significant unstable medical disorders, life-threatening disease, or current malignancies.
- •14.Demonstrates a positive test result for Hepatitis B surface antigen, Hepatitis C antibody or HIV antibody.
- •15.Reports simultaneous participation in any other drug trial or participation in any other trial involving investigational medicinal product within 30 days of randomization. However, subjects can be enrolled considering elimination half-life of study drug of last participation and/or pharmacokinetic profile of such drug molecule of last participation and/or other medical judgment (if any) to justify the subjectâ??s participation based on investigator opinion and/or sponsor medical monitor.
- •16.Any other conditions that in the investigatorâ??s judgment, might compromise subject safety or affect study results.
- •17.Abnormal baseline findings considered by the investigator to indicate conditions that might affect study endpoints and/or might increase the risk to the subject or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.
- •18.Employees of the Investigator or research centre or their immediate family members
研究者
相似试验
Unknown
不适用
A randomized, double-blind, Placebo-controlled, three arms, parallel-group, multiple-site bioequivalence study with clinical endpointsCTRI/2018/11/016407Encube Ethicals Private Ltd13
已完成
不适用
To evaluate the Bio equivalence of two Tacrolimus 0.03% topical Ointment formulations in adult patients with moderate to Severe Atopic DermatitisCTRI/2016/03/006735Intas Pharmaceuticals Ltd346
招募中
3 期
A study to evaluate effectiveness of Tacrolimus 0.1% Topical Ointment in the patients of the allergic dermatitis.CTRI/2012/05/002636Accord Healthcare Ltd650
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-controlled, Three-arm, Parallel Assignment, Multi-centre, Therapeutic Equivalence Study of Two Tacrolimus 0.1% Topical Ointment Formulations in Adult Patients with Moderate to Severe Atopic Dermatitismoderate to severe atopic dermatitisMedDRA version: 17.0Level: PTClassification code 10012438Term: Dermatitis atopicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2011-006236-23-PLAccord Healthcare Ltd.650
进行中（未招募）
3 期
To understand the safety and outcome of Tacrolimus ointment 0.1% in patients suffering from Atopic dermatitisCTRI/2023/05/052282JAMP Pharma Corporation